Register / Log In

Clinical Pharmacology

Support consumer access to specialty medications through value-based insurance design
The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
NIH partners with industry to find best biological targets of disease
The National Institutes of Health, FDA, 10 biopharmaceutical companies, the Pharmaceutical Research and Manufacturers of America, and several nonprofit organizations have launched an unprecedented public/private partnership to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development.
Stricter bioequivalence rules may be needed for generic antiepilepsy treatments

Future of dermatologic innovation has bright spots
While government funds for research in dermatology and other medical specialties seems to be dwindling, there are forces at work that could help to pick up at least part of the slack.
FDA approves new once-daily treatment option for HIV
Dolutegravir, a new, once-daily option, may allow improved personalization of a patient’s medication regimen.
FDA approves 4PCC for acute major bleeding
CSL Behring's Kcentra is is currently the only 4-factor PCC available in the United States.
Bariatric surgery affects postoperative warfarin dosing
A small study of patients undergoing bariatric surgery suggests that weekly warfarin doses can change by as much as 20% postoperatively.
Many patients with AF lack indication for aspirin use
ORBIT-AF study results indicate that the benefit of adding aspirin therapy to oral anticoagulation for atrial fibrillation patients is unclear.
FDA approves acyclovir buccal tablets for recurrent herpes labialis
Patients randomized to acyclovir MBT experienced less time from prodromal symptoms to healing; more patients had abortive episodes that did not progress to vesicular lesions; and duration of abortive episodes was briefer.
FDA approves first drug to treat two forms of pulmonary hypertension
Before the approval of riociguat, there was no approved nonsurgical therapy for chronic thromboembolic pulmonary hypertension.